Follow us on Twitter
twitter icon@FreshPatents


Elan patents

      

This page is updated frequently with new Elan-related patent applications.




 P97 fusion proteins patent thumbnailnew patent P97 fusion proteins
Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (bbb) and/or improve tissue penetration of the antibody in cns and peripheral tissues, and thereby treat and/or diagnose her2-positive cancers, including those of the central nervous system (cns).. .
Bioasis Technologies, Inc.


 Histone demethylase inhibitors patent thumbnailnew patent Histone demethylase inhibitors
Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase.
Celgene Quanticel Research, Inc.


 Histone demethylase inhibitors patent thumbnailnew patent Histone demethylase inhibitors
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.


 Use of encapsulated cell therapy for treatment of ophthalmic disorders patent thumbnailnew patent Use of encapsulated cell therapy for treatment of ophthalmic disorders
Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ect) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia..
Neurotech Usa, Inc.


 Transgenic mouse models for mc4r patent thumbnailnew patent Transgenic mouse models for mc4r
There are provided herein transgenic non-human animals and cells comprising a transgene encoding either a mutated human melanocortin type-4 receptor (hmc4r) protein, wherein the mutated protein is misfolded and retained intracellularly, or a wild-type human melanocortin type-4 receptor (hmc4r) protein. Transgenes and targeting constructs used to produce such transgenic animals and cells are also provided, as well as methods for using the transgenic animals in pharmaceutical screening and as commercial research animals for modeling obesity..
Universite De Montreal


 Mir-211 expression and related pathways in human melanoma patent thumbnailMir-211 expression and related pathways in human melanoma
Provided herein are methods for the diagnosis of human melanoma by assessing mitf, mir-211, trpm1, and/or kcnma1 and methods for the diagnosis of resistance to chemotherapeutic agents by assessing the regulatory pathways of pgc1α. Methods for treating melanoma, including drug-resistant melanoma, are also provided..
Sanford-burnham Medical Research Institute


 Peptides derived from gse 24.2 for treating diseases caused by oxidative stress and damage to dna patent thumbnailPeptides derived from gse 24.2 for treating diseases caused by oxidative stress and damage to dna
This invention relates to a polypeptide which comprises the fragment seq id no. 2 of peptide gse24.2 (seq id no.
Centro De InvestigaciÓn BiomÉdica En Red (ciber)


 Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody patent thumbnailTreatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
The invention provides a method of treating a melanoma comprising (i) identifying a patient having a pd-l1-negative melanoma and (ii) administering to the patient a combination of an anti-pd-1 antibody or an antigen-binding portion thereof and an anti-ctla-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration..
Bristol-myers Squibb Company


 Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms patent thumbnailCompositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma, a variety of pd-l1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.. .
Dana-farber Camcer Institute, Inc.


 Skin lightener in phototherapy patent thumbnailSkin lightener in phototherapy
The invention relates, inter alia, to melanin synthesis inhibitors for use in treating skin illnesses, wherein the skin is additionally irradiated with an artificial radiation source. The invention further relates to cosmetic treatments..
Merck Patent Gmbh


Composite comprising 3'-hydroxygenistein and use for inhibition of melanogenesis

A composite comprising 3′-hydroxygenistein and a use for inhibition of melanogenesis are revealed herein. An effective dose of 3′-hydroxygenistein is applied to skin for inhibition of tyrosinase activity and further inhibition of melanogensis, so that 3′-hydroxygenistein can be used in cosmetic composition..
National University Of Tainan

Display apparatus

Provided is a display apparatus and a method of manufacture. The display apparatus includes a first substrate with a plurality of organic electroluminescence devices, a second substrate with a color filter, the second substrate facing the first substrate, and an adhesive layer disposed between the first substrate and the second substrate so as to cover the plurality of organic electroluminescence devices, the adhesive layer being made of a material selected from the group consisting of a phenol resin, a melanin resin, an unsaturated polyester resin, an epoxy resin, a silicon resin and a polyurethane resin..
Joled Inc.

Display apparatus

Provided is a display apparatus and a method of manufacture. The display apparatus includes a first substrate with a plurality of organic electroluminescence devices, a second substrate with a color filter, the second substrate facing the first substrate, and an adhesive layer disposed between the first substrate and the second substrate so as to cover the plurality of organic electroluminescence devices, the adhesive layer being made of a material selected from the group consisting of a phenol resin, a melanin resin, an unsaturated polyester resin, an epoxy resin, a silicon resin and a polyurethane resin..
Joled Inc.

System and controlling g-protein coupled receptor pathways

A light-sensitive g-protein coupled receptor includes a light sensitive extracellular cone opsin or melanopsin domain and a hetorologous intracellular domain capable of modulating an intracellular signaling pathway.. .
Case Western Reserve University

Histone demethylase inhibitors

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Compositions and methods for treating melanoma

Toll-like receptor (tlr) agonists can induce chemokine production. We find that tlr2 and tlr6 are widely expressed on human melanoma cells, and that tlr2/6 agonists (malp-2 or fsl-1) synergize with interferon-gamma (ifnγ) to induce production of cxcl10 from melanoma cells.
University Of Virginia Patent Foundation

Treatment and diagnosis of melanoma

The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods..
The Rockefeller University

Industrial process equipment cleaning of ester-based soils and materials utilizing acyl transfer reactions

A non-caustic cleaning composition and methods and uses thereof are described. The non-caustic cleaning composition can include an amine source that removes ester-based soils and materials via an acyl transfer reaction.
Rochester Midland Corporation

5'-substituted nucleoside compounds

The present invention relates to novel 5′-substituted nucleoside compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer, in particular glioblastomas, melanoma, sarcomas, gastric cancer, pancreatic cancer, cholangiocarcinoma, bladder cancer, breast cancer, non-small cell lung cancer, leukemias including acute myeloid leukemia, and lymphomas.. .
Eli Lilly And Company

Fragments of p97 and uses thereof

Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (bbb) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the bbb.. .
Bioasis Technologies, Inc.

Treatment of eye disease

A method of treating an eye disease comprising administering an adeno-associated virus (aav) vector to a mammalian subject by subretinal injection, wherein the aav vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.. .
Isis Innovation Limited

Treatment of diabetes with pentacyclic triterpenoid saponin compounds from szechuan melandium root

The method for treating diabetes in an individual includes the step of administering a therapeutically effective amount of a pharmaceutically acceptable pentacyclic triterpenoid saponin compound to the individual suitable to provide therapeutic levels of insulin to the individual. The compound can be administered by injection, transdermal contact, or nasal spray.

Melanocortin receptor-specific peptides

Where r1, r2, r3, r4, r5, r6, r7, r8, r9, r10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.. .

Compound, composition, and protecting skin from high energy visible light

A compound, composition, and method for the protection of skin from the harmful effects of radiation, and particularly the harmful effects of high energy visible (hev) radiation, are disclosed. The compound is a melanin derivative that can be formulated into compositions containing the melanin derivative and a suitable carrier.
Photoprotective Technologies, Inc.

Method of improving the appearance of skin and compositions therefor

A cosmetic method for reducing the level of high-mobility group protein b1 released from keratinocytes. The method includes identifying a target portion of skin where reduction of hmgb1 level is desired, and topically applying a nicotinamide riboside containing cosmetic composition to the target portion of skin during a treatment period, which is sufficient to reduce the level of hmgb1 released by keratinocytes.
The Procter & Gamble Company

Assays and methods relating to the treatment of melanoma

The technology described herein relates to assays and methods for the diagnosis, prognosis, and/or treatment of melanoma, e.g. Relating to measuring the level of neurophilin-2 (nrp-2) mrna expressed in melanoma cells.
Trustees Of Boston University

Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

The present invention relates to an opioid antagonist with κ-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with κ-activity and vortioxetine for use in treatment of depressive disorder with melancholic features.
H. Lundbeck A/s

Molasses binder

A binder based predominantly on molasses which incorporates both polymeric and monomeric polycarboxylic acid components to form a composite including both melanoidin and polyester polymeric structures. The binder incorporates the chemical profile of molasses with a mixture of polycarboxylic acids which combines to form a strong and weatherable binder composition which may be used to bind loosely or non-assembled matter..
Knauf Insulation, Inc.

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

Novel antibodies and antigen binding fragments that specifically bind to kaag1 and which may be used in the treatment, detection and diagnosis of cancer comprising kaag1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
Alethia Biotherapeutics Inc.

Treating cancer

This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided..
Mayo Foundation For Medical Education And Research

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.



Elan topics:
  • Folic Acid
  • Carbon Dioxide
  • Antibodies
  • Immune Response
  • High Energy
  • Inorganic Compounds
  • Electrolysis
  • Semiconductor Material
  • Semiconductor
  • Hydrogen Production From Water
  • Female Sexual Dysfunction
  • Dysfunction
  • Sexual Dysfunction
  • Mammography
  • Radiograph


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Elan for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Elan with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.9738

    file did exist - 2170

    1 - 1 - 52